Agalimmune Limited was established in 2013 and is headquartered in London, UK with laboratories in Sandwich, UK.
Agalimmune licensed the Alphaject™ technology from the University of Massachusetts Medical School, Worcester, MA (USA) where it was researched and developed by a team led by Professor Uri Galili. The goal of Alphaject™ therapy is to activate a patient-specific tumour-antigen targeted immune response in patients with solid tumors. This treatment may also bring about a long-lasting protective anti-tumor immune response.
Agalimmune will work with key collaborators to further research, develop and commercialize the technology for the benefit of cancer patients.
Alphaject™ is a registered trademark of Agalimmune Ltd.